Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: Experiment with mice

National Medical Journal of China

Volumn 86, Issue 44, 2006, Pages 3109-3113

  Huang, Xiang Gang ^a   Xu, Jian Qing ^a   Ren, Li ^a   Qiu, Chao ^a   Zhang, Ning ^a   Liu, Lian Xing ^a   Wan, Yan Min ^a   Peng, Hong ^a   Shao, Yi Ming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

DNA; HIV 1; Immunity; Mucosal; Vaccinces

Indexed keywords

CHOLERA TOXIN; DNA VACCINE; GAMMA INTERFERON ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS DNA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LUNG LAVAGE; LYMPHOCYTE FUNCTION; MOUSE; NASOPHARYNX; NONHUMAN; NOSE MUCUS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SPLEEN CELL; VACCINIA VIRUS;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; MICE; MICE, INBRED BALB C; NASAL MUCOSA; RANDOM ALLOCATION; T-LYMPHOCYTES; VACCINES, DNA;

EID: 33846404514     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Czerkinsky C, Anjuere F, McGhee JR, et al. Mucosal immunity and tolerance: relevance to vaccine development. J Immunol Rev, 1999, 170:197-222.
2. Bradney CP, Sempowski GD, Liao HX, et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virology, 2002, 76: 517-524.
3. Duan X, Jia SF, Koshkina N, et al. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer, 2006,106:1382-1388.
4. Zhang H, Fayad R, Wang X, et al. Human immunodeficiency virus type 1 Gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding Gag. J Virol, 2004, 78: 10249-10257.
5. Belykov IM, Ahlers JD, Brandwein BY, et al. The importance of local mucosal HIV-specific CD8 + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest, 1998,102: 2072-2081.
6. Kent SJ, Dale CJ, Ranasinghe C, et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine,2005, 23:5009-5021.
7. Sankaran S, Guadalupe M, Reay E, et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci USA, 2005,102:9860-9865.
8. Walker RI. New strategies for using mucosal vacciniation to achieve more effective immunization. Vaccine,1994, 12:387-400.
9. Kyd JM, Cripps AW. Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. J Biotech, 2000, 83:85-90.
10. Borsutzky S, Ebensen T, Link C, et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine, 2006,24:2049-2056.
11. Belyakov IM, Ahlers JD, Berzofsky JA. Mucosal AIDS vaccines: current status and future directions. Expert Rev Vaccines,2004, 3: S65-73.
12. Nakaya Y, Zheng H, Garcia-Sastre A. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine, 2003, 21:2097-2106.
13. Matoba N, Magerus A, Geyer BC, et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA, 2004,101:13584-13589.
14. Chinese source. 2005, 85:2629-2635.
15. Yoshino N, Lu FX, Fujihashi K, et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J Immunol, 2004, 173:6850-6857.
16. Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res,1997,16:187.
17. Buonaguro L, Visciano ML, Tornesello ML, et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol, 2005,79:7059-7067.
18. Castaldello A, Brocca-Cofano E, Voltan R, et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine, 2006, 24:5655-5669.
19. Someya K, Ami Y, Nakasone T, et al. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J Immunol, 2006,176: 1784-1795.
20. Kleemann E, Neu M, Jekel N, et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release, 2005,109:299-316.